Latest Cangene Corp (CGNOF) Headlines Emergen
Post# of 3
Posted On: 03/09/2014 7:26:01 AM
Latest Cangene Corp (CGNOF) Headlines
Emergent BioSolutions Completes Acquisition of Cangene Corporation
Business Wire - Fri Feb 21, 10:20AM CST
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects to receive approximately $40 million of cash from Cangene in connection with closing. The completion of the acquisition follows the successful conclusion of all closing conditions, including approval by the Ontario Superior Court of Justice and a positive vote by Cangene shareholders at a special shareholder meeting held on February 12, 2014. The transaction is consistent with Emergent's growth plan in that it diversifies the company's revenue mix, adds commercial product sales and contributes to earnings growth.
Emergent BioSolutions Announces Completion of $250 Million Convertible Senior Notes Offering
Business Wire - Wed Jan 29, 3:01PM CST
Emergent BioSolutions Inc. (NYSE: EBS) announced today the closing of its previously announced offering of 2.875% Convertible Senior Notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. Emergent issued $250 million aggregate principal amount of its notes, which includes the additional $35 million principal amount of notes purchased by the initial purchasers under the exercise of the option granted to them by the company.
Emergent BioSolutions Announces Expiration of the Hart-Scott-Rodino Waiting Period for Emergent's Acquisition of Cangene Corporation
Business Wire - Tue Jan 28, 6:00AM CST
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Emergent's proposed acquisition of Cangene Corporation (TSX: CNJ), has expired. The expiration of the waiting period for antitrust review of the proposed acquisition satisfies one of the conditions to the closing of the acquisition.
Emergent BioSolutions Announces Pricing of Offering of $215 Million of 2.875% Convertible Senior Notes
Business Wire - Thu Jan 23, 6:58PM CST
Emergent BioSolutions Inc. ("Emergent") (NYSE: EBS) announced today the pricing of its offering of $215 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), which was upsized from the previously announced $200 million offering. Emergent also granted the initial purchasers an option to purchase up to an additional $35 million aggregate principal amount of the Notes.
Emergent BioSolutions Announces Proposed Offering of $200 Million Convertible Senior Notes
Business Wire - Wed Jan 22, 3:01PM CST
Emergent BioSolutions Inc. ("Emergent") (NYSE: EBS) announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Emergent also intends to grant the initial purchasers an option to purchase up to an additional $30 million aggregate principal amount of the Notes.
Global Hemophilia Clinical Trials Review, H2 2013 Analysis
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc4lwr/hemophilia_global) has announced the addition of the "Hemophilia Global Clinical Trials Review, H2, 2013" report to their offering. Hemophilia Global Clinical Trials Review, H2, 2013" provides data on the Hemophilia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemophilia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemophilia. Reasons to buy: - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Hemophilia Therapeutics Clinical Trials - Novo Nordisk A/S - Pfizer Inc. - Bayer AG - Baxter International Inc. - Baxter Healthcare Corporation - Octapharma AG - CSL Limited - Biogen Idec Inc. - CSL Behring LLC - Prolor Biotech, Inc. - Grifols, S.A. - rEVO Biologics - UMC Utrecht Holding BV - Green Cross Corporation - Recoly N.V. . - LFB Biotechnologies, S.A.S - Cangene Corporation - Chugai Pharmaceutical Co., Ltd. - Octapharma Limited - Inspiration BioPharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/cc...lia_global
Global Smallpox Clinical Trials Review, H2, 2013
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xg46m/smallpox_global) has announced the addition of the "Smallpox Global Clinical Trials Review, H2, 2013" report to their offering. Smallpox Global Clinical Trials Review, H2, 2013" provides data on the Smallpox clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Smallpox. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Smallpox. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Smallpox Therapeutics Clinical Trials - Bavarian Nordic A/S - Sanofi - SIGA Technologies, Inc. - Cangene Corporation - Chimerix, Inc. - Sanofi Pasteur, Inc. - VaxGen, Inc. (Inactive) - DynPort Vaccine Company LLC For more information visit http://www.researchandmarkets.com/research/3x...pox_global
IIROC Trade Resumption - Cangene Corporation
Newsfile Corp - Thu Sep 19, 9:55AM CDT
Trading resumes in:
IIROC Trade Halt - Cangene Corporation
Newsfile Corp - Thu Sep 19, 8:32AM CDT
The following issues have been halted by IIROC:
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hemophilia A - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Hemophilia
M2 - Wed Sep 04, 12:25PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v3889m/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Hemophilia A - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia A. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Hemophilia A. - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia A pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - BioMarin Pharmaceutical Inc. - Dong-A Pharmaceutical Co., Ltd. - Octapharma AG - Pfizer Inc. - Bayer AG - PROLOR Biotech, Inc. - ReGenX Biosciences, LLC - Amarna Therapeutics B.V. - EpiVax, Inc. - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - PolyTherics Limited - Celtic Pharmaceutical Holdings L.P. For more information visit http://www.researchandmarkets.com/research/v3...mophilia_a About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development
Clostridium Infections - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:16AM CDT
Research and Markets has announced the addition of the "Clostridium Infections - Pipeline Review, H1 2013" (http://www.researchandmarkets.com/research/p9lxmj/clostridium) report to their offering. 'Clostridium Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Clostridium Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by u
FFF Enterprises Named Exclusive Distributor of Cangene's VARIZIG(R)
Marketwire - Thu Feb 28, 8:00AM CST
FFF Enterprises, Inc. announced today that it will remain the exclusive distributor for VARIZIG [Varicella Zoster Immune Globulin (Human)], a hyperimmune manufactured by Cangene Corporation. VARIZIG is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk patient groups including immunocompromised children, newborns and pregnant women. VARIZIG is intended to reduce the severity of chickenpox infections in these patients. It is the only FDA-approved immune globulin for chickenpox, after exposure, available in the United States. FFF also partnered with Cangene as sole distributor of VARIZIG during its investigational new drug (IND) Expanded Access Protocol and clinical trial phases.
Inspiration Biopharmaceuticals and Ipsen Announce Closing of the IB1001 Sale to Cangene Corporation
Business Wire - Wed Feb 20, 12:30AM CST
Inspiration Biopharmaceuticals (Inspiration) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation (TSX: CNJ) (Cangene). The transaction was announced on February 6, 2013. Ipsen and Inspiration jointly agreed to sell their respective commercialization rights to IB1001 as part of the transaction. Cangene acquired worldwide rights to IB1001, a recombinant factor IX currently under regulatory review in the United States and Europe. This transaction follows the announcement last month that Inspiration and Ipsen had agreed to sell OBI-1 (recombinant porcine FVIII) to Baxter International.
Ipsen and Inspiration Biopharmaceuticals Announce Closing of the IB1001 Sale to Cangene Corporation
Business Wire - Wed Feb 20, 12:30AM CST
Regulatory News:
Celtic Pharma Welcomes the Results of the Sale Process of Inspiration Biopharmaceutical's Hemophilia Assets to Cangene Corporation (TSX: CNJ)
Business Wire - Thu Feb 07, 3:43AM CST
Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") records today's announcement by Inspiration Biopharmaceuticals ("Inspiration") that it has successfully concluded the sale of its hemophilia product portfolio for an aggregate consideration that could exceed $1 billion. Celtic Pharma holds a substantial minority stake in Inspiration, and will participate in the transaction proceeds in accordance with an agreement reached between Ipsen as Debtor-in-Possession and the non-Ipsen stakeholders.
Ipsen and Inspiration Biopharmaceuticals sign Asset Purchase Agreement with Cangene Corporation on IB1001
M2 - Wed Feb 06, 8:21AM CST
Speciality-driven pharmaceutical company Ipsen (Euronext:IPN) and Inspiration Biopharmaceuticals Inc today announced the signing of an Asset Purchase Agreement (APA) under which Cangene Corporation has agreed to acquire the worldwide rights to IB1001, a recombinant factor IX (rFIX) for the treatment of haemophilia B.
Inspiration Biopharmaceuticals and Ipsen Complete Sale Process for All Hemophilia Assets
Business Wire - Wed Feb 06, 7:26AM CST
--Cangene Corporation will acquire worldwide rights to IB1001 (recombinant factor IX)
Emergent BioSolutions Completes Acquisition of Cangene Corporation
Business Wire - Fri Feb 21, 10:20AM CST
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects to receive approximately $40 million of cash from Cangene in connection with closing. The completion of the acquisition follows the successful conclusion of all closing conditions, including approval by the Ontario Superior Court of Justice and a positive vote by Cangene shareholders at a special shareholder meeting held on February 12, 2014. The transaction is consistent with Emergent's growth plan in that it diversifies the company's revenue mix, adds commercial product sales and contributes to earnings growth.
Emergent BioSolutions Announces Completion of $250 Million Convertible Senior Notes Offering
Business Wire - Wed Jan 29, 3:01PM CST
Emergent BioSolutions Inc. (NYSE: EBS) announced today the closing of its previously announced offering of 2.875% Convertible Senior Notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. Emergent issued $250 million aggregate principal amount of its notes, which includes the additional $35 million principal amount of notes purchased by the initial purchasers under the exercise of the option granted to them by the company.
Emergent BioSolutions Announces Expiration of the Hart-Scott-Rodino Waiting Period for Emergent's Acquisition of Cangene Corporation
Business Wire - Tue Jan 28, 6:00AM CST
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Emergent's proposed acquisition of Cangene Corporation (TSX: CNJ), has expired. The expiration of the waiting period for antitrust review of the proposed acquisition satisfies one of the conditions to the closing of the acquisition.
Emergent BioSolutions Announces Pricing of Offering of $215 Million of 2.875% Convertible Senior Notes
Business Wire - Thu Jan 23, 6:58PM CST
Emergent BioSolutions Inc. ("Emergent") (NYSE: EBS) announced today the pricing of its offering of $215 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), which was upsized from the previously announced $200 million offering. Emergent also granted the initial purchasers an option to purchase up to an additional $35 million aggregate principal amount of the Notes.
Emergent BioSolutions Announces Proposed Offering of $200 Million Convertible Senior Notes
Business Wire - Wed Jan 22, 3:01PM CST
Emergent BioSolutions Inc. ("Emergent") (NYSE: EBS) announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Emergent also intends to grant the initial purchasers an option to purchase up to an additional $30 million aggregate principal amount of the Notes.
Global Hemophilia Clinical Trials Review, H2 2013 Analysis
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc4lwr/hemophilia_global) has announced the addition of the "Hemophilia Global Clinical Trials Review, H2, 2013" report to their offering. Hemophilia Global Clinical Trials Review, H2, 2013" provides data on the Hemophilia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemophilia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemophilia. Reasons to buy: - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Hemophilia Therapeutics Clinical Trials - Novo Nordisk A/S - Pfizer Inc. - Bayer AG - Baxter International Inc. - Baxter Healthcare Corporation - Octapharma AG - CSL Limited - Biogen Idec Inc. - CSL Behring LLC - Prolor Biotech, Inc. - Grifols, S.A. - rEVO Biologics - UMC Utrecht Holding BV - Green Cross Corporation - Recoly N.V. . - LFB Biotechnologies, S.A.S - Cangene Corporation - Chugai Pharmaceutical Co., Ltd. - Octapharma Limited - Inspiration BioPharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/cc...lia_global
Global Smallpox Clinical Trials Review, H2, 2013
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xg46m/smallpox_global) has announced the addition of the "Smallpox Global Clinical Trials Review, H2, 2013" report to their offering. Smallpox Global Clinical Trials Review, H2, 2013" provides data on the Smallpox clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Smallpox. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Smallpox. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Smallpox Therapeutics Clinical Trials - Bavarian Nordic A/S - Sanofi - SIGA Technologies, Inc. - Cangene Corporation - Chimerix, Inc. - Sanofi Pasteur, Inc. - VaxGen, Inc. (Inactive) - DynPort Vaccine Company LLC For more information visit http://www.researchandmarkets.com/research/3x...pox_global
IIROC Trade Resumption - Cangene Corporation
Newsfile Corp - Thu Sep 19, 9:55AM CDT
Trading resumes in:
IIROC Trade Halt - Cangene Corporation
Newsfile Corp - Thu Sep 19, 8:32AM CDT
The following issues have been halted by IIROC:
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hemophilia A - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Hemophilia
M2 - Wed Sep 04, 12:25PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v3889m/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Hemophilia A - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia A. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Hemophilia A. - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia A pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Baxter International Inc. - Biogen Idec Inc. - AstraZeneca PLC - Cangene Corporation - Lentigen Corporation - Sangamo BioSciences, Inc. - Pharming Group N.V. - Novo Nordisk A/S - BioMarin Pharmaceutical Inc. - Dong-A Pharmaceutical Co., Ltd. - Octapharma AG - Pfizer Inc. - Bayer AG - PROLOR Biotech, Inc. - ReGenX Biosciences, LLC - Amarna Therapeutics B.V. - EpiVax, Inc. - Expression Therapeutics LLC - Asklepios BioPharmaceutical, Inc. - Amunix, Inc. - PolyTherics Limited - Celtic Pharmaceutical Holdings L.P. For more information visit http://www.researchandmarkets.com/research/v3...mophilia_a About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development
Clostridium Infections - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:16AM CDT
Research and Markets has announced the addition of the "Clostridium Infections - Pipeline Review, H1 2013" (http://www.researchandmarkets.com/research/p9lxmj/clostridium) report to their offering. 'Clostridium Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Clostridium Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by u
FFF Enterprises Named Exclusive Distributor of Cangene's VARIZIG(R)
Marketwire - Thu Feb 28, 8:00AM CST
FFF Enterprises, Inc. announced today that it will remain the exclusive distributor for VARIZIG [Varicella Zoster Immune Globulin (Human)], a hyperimmune manufactured by Cangene Corporation. VARIZIG is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk patient groups including immunocompromised children, newborns and pregnant women. VARIZIG is intended to reduce the severity of chickenpox infections in these patients. It is the only FDA-approved immune globulin for chickenpox, after exposure, available in the United States. FFF also partnered with Cangene as sole distributor of VARIZIG during its investigational new drug (IND) Expanded Access Protocol and clinical trial phases.
Inspiration Biopharmaceuticals and Ipsen Announce Closing of the IB1001 Sale to Cangene Corporation
Business Wire - Wed Feb 20, 12:30AM CST
Inspiration Biopharmaceuticals (Inspiration) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation (TSX: CNJ) (Cangene). The transaction was announced on February 6, 2013. Ipsen and Inspiration jointly agreed to sell their respective commercialization rights to IB1001 as part of the transaction. Cangene acquired worldwide rights to IB1001, a recombinant factor IX currently under regulatory review in the United States and Europe. This transaction follows the announcement last month that Inspiration and Ipsen had agreed to sell OBI-1 (recombinant porcine FVIII) to Baxter International.
Ipsen and Inspiration Biopharmaceuticals Announce Closing of the IB1001 Sale to Cangene Corporation
Business Wire - Wed Feb 20, 12:30AM CST
Regulatory News:
Celtic Pharma Welcomes the Results of the Sale Process of Inspiration Biopharmaceutical's Hemophilia Assets to Cangene Corporation (TSX: CNJ)
Business Wire - Thu Feb 07, 3:43AM CST
Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") records today's announcement by Inspiration Biopharmaceuticals ("Inspiration") that it has successfully concluded the sale of its hemophilia product portfolio for an aggregate consideration that could exceed $1 billion. Celtic Pharma holds a substantial minority stake in Inspiration, and will participate in the transaction proceeds in accordance with an agreement reached between Ipsen as Debtor-in-Possession and the non-Ipsen stakeholders.
Ipsen and Inspiration Biopharmaceuticals sign Asset Purchase Agreement with Cangene Corporation on IB1001
M2 - Wed Feb 06, 8:21AM CST
Speciality-driven pharmaceutical company Ipsen (Euronext:IPN) and Inspiration Biopharmaceuticals Inc today announced the signing of an Asset Purchase Agreement (APA) under which Cangene Corporation has agreed to acquire the worldwide rights to IB1001, a recombinant factor IX (rFIX) for the treatment of haemophilia B.
Inspiration Biopharmaceuticals and Ipsen Complete Sale Process for All Hemophilia Assets
Business Wire - Wed Feb 06, 7:26AM CST
--Cangene Corporation will acquire worldwide rights to IB1001 (recombinant factor IX)
(0)
(0)Cangene Corp (CGNOF) Stock Research Links
Scroll down for more posts ▼